Cipla revs up for generic Sovaldi launch in India

Cipla is rolling out its low-cost version of Gilead Sciences’ hep C powerhouse Sovaldi in India. With a launch planned this week, Cipla will become the latest company to field a Sovaldi copycat under Gilead’s deal with generic drugmakers. The Indian pharma will market the drug under the name “Hepcvir,” bringing the Sovaldi copycat to an estimated 12 million to 18 million hep C patients in the country, The Economic Times reports.

Read the source article at Pharma News

About the Author

Leave a Reply